The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle

Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy

(2021) Jianhua Liu et al.   MATERIALS & DESIGN

Sustained and targeted delivery of checkpoint inhibitors by metal-organic frameworks for cancer immunotherapy

(2021) Shahad K. Alsaiari et al.   Science Advances

Ultrasound-Augmented Mitochondrial Calcium Ion Overload by Calcium Nanomodulator to Induce Immunogenic Cell Death

(2021) Pan Zheng et al.   NANO LETTERS

Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models

(2021) Yao-Xin Lin et al.   Science Translational Medicine

FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1

(2020) Preeti Narayan et al.   CLINICAL CANCER RESEARCH

Atezolizumab for the treatment of breast cancer

(2020) Sangeetha M. Reddy et al.   Expert Review of Anticancer Therapy

TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer

(2020) Danhua Xu et al.   IMMUNOBIOLOGY

Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity

(2020) Christopher E. Rudd et al.   Cell Reports

Nanomaterials for Combinational Radio–Immuno Oncotherapy

(2020) Juan Wang et al.   ADVANCED FUNCTIONAL MATERIALS

Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients

(2020) Miwa Noda et al.   ANNALS OF SURGICAL ONCOLOGY

Expression of the immune checkpoint VISTA in breast cancer

(2020) Liju Zong et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

(2020) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells

(2020) Elham Masoumi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types

(2020) Mayanne M. T. Zhu et al.   MODERN PATHOLOGY

LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

(2020) Niklas Klümper et al.   Journal for ImmunoTherapy of Cancer

Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer

(2020) Jian-Lei Wu et al.   GYNECOLOGIC ONCOLOGY

Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro

(2020) Keyvan Fallah-Mehrjardi et al.   IMMUNOLOGY LETTERS

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

(2020) J. A. Kyte et al.   Journal of Translational Medicine

Tackling autoimmunity with nanomedicines

(2020) Xiangru Feng et al.   Nanomedicine

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants

(2020) Reem Saleh et al.   Genes

Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy

(2020) Xiangru Feng et al.   Science Bulletin

Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy

(2020) Yajie Sun et al.   Asian Journal of Pharmaceutical Sciences

Targeting the A2AR in cancer; early lessons from the clinic

(2020) Stephen B Willingham et al.   CURRENT OPINION IN PHARMACOLOGY

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

(2020) Elizabeth A Mittendorf et al.   LANCET

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells

(2020) Demet Candas-Green et al.   Nature Communications

TIGIT in cancer immunotherapy

(2020) Joe-Marc Chauvin et al.   Journal for ImmunoTherapy of Cancer

The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities

(2020) Mohammad-Javad Sanaei et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Intercalation of curcumin into liposomal chemotherapeutic agent augments apoptosis in breast cancer cells

(2020) Reza Mahmoudi et al.   JOURNAL OF BIOMATERIALS APPLICATIONS

Nanoparticle-mediated internal radioisotope therapy to locally increase the tumor vasculature permeability for synergistically improved cancer therapies

(2019) Chao Liang et al.   BIOMATERIALS

Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells

(2019) Miriam Victoria Martín-Manzo et al.   PATHOLOGY & ONCOLOGY RESEARCH

Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes

(2019) Yanheng Wu et al.   Nanomedicine

Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading

(2019) Jeremy Force et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors

(2019) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

(2019) Nina D’Abreo et al.   Nature Reviews Clinical Oncology

Phototherapy using immunologically modified carbon nanotubes to potentiate checkpoint blockade for metastatic breast cancer

(2019) Yong Li et al.   Nanomedicine-Nanotechnology Biology and Medicine

Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer

(2019) Di (Maria) Jiang et al.   Oncotarget

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation

(2019) Daniela Pende et al.   Frontiers in Immunology

The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer

(2019) Inna M. Yasinska et al.   Frontiers in Immunology

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer

(2019) Cinzia Solinas et al.   Cancers

Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle

(2019) Guorui Li et al.   ACS Applied Materials & Interfaces

Enhancing Triple Negative Breast Cancer Immunotherapy by ICG‐Templated Self‐Assembly of Paclitaxel Nanoparticles

(2019) Bing Feng et al.   ADVANCED FUNCTIONAL MATERIALS

LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

(2019) P Schmid et al.   ANNALS OF ONCOLOGY

Recent advances in nanotheranostics for triple negative breast cancer treatment

(2019) Vikram Thakur et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer

(2019) Rui Zhang et al.   Small

Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

(2019) Anna Galstyan et al.   Nature Communications

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

(2019) Hauke Stamm et al.   OncoImmunology

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells

(2019) Beatris Mastelic-Gavillet et al.   Journal for ImmunoTherapy of Cancer

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells

(2019) Saleh et al.   Vaccines

TIGIT as an emerging immune checkpoint

(2019) H. Harjunpää et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade

(2018) Shuangjiang Yu et al.   ADVANCED MATERIALS

TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer

(2018) Álvaro de Mingo Pulido et al.   CANCER CELL

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

(2018) Silvia C. Formenti et al.   CLINICAL CANCER RESEARCH

Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma

(2018) Divya Sekar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer

(2018) Yunxuan Wang et al.   Journal of Breast Cancer

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer

(2018) Lina Liu et al.   MOLECULAR THERAPY

NPP1 is responsible for potent extracellular ATP hydrolysis as NTPDase1 in primary cultured murine microglia

(2018) Hye Min Lim et al.   Purinergic Signalling

Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs

(2018) Li Liu et al.   Breast Cancer

Delivery Strategies for Immune Checkpoint Blockade

(2018) Qian Chen et al.   Advanced Healthcare Materials

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer

(2018) Varun Sasidharan Nair et al.   Clinical Epigenetics

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

TIGIT: a novel immunotherapy target moving from bench to bedside

(2018) Benjamin L. Solomon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy

(2018) Oliviero Marinelli et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

VSIG-3 as a ligand of VISTA inhibits human T cell function

(2018) Jinghua Wang et al.   IMMUNOLOGY

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

(2018) Ralf Kleef et al.   INTEGRATIVE CANCER THERAPIES

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

(2018) Marleen Kok et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune Checkpoint Inhibitor Toxicity

(2018) David J. Palmieri et al.   Current Oncology Reports

TIM-3 expression in breast cancer

(2018) Samantha Burugu et al.   OncoImmunology

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

(2018) Leisha A. Emens et al.   JAMA Oncology

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

(2018) S Adams et al.   ANNALS OF ONCOLOGY

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure

(2017) Eunyoung Tak et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function

(2017) Xi Chen et al.   Oncotarget

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

(2017) Chao Wang et al.   Nature Biomedical Engineering

Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer

(2016) In Hae Park et al.   Clinical Breast Cancer

Prognostic significance of PD-L1 and PD-L2 in breast cancer

(2016) Mauricio Z. Baptista et al.   HUMAN PATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation

(2016) Shi-Yong Li et al.   JOURNAL OF CONTROLLED RELEASE

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma

(2016) Zhu Li et al.   MEDICINE

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

(2016) Dickran Kazandjian et al.   ONCOLOGIST

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

(2016) Yichao Chen et al.   Nature Communications

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

(2016) Chunbai He et al.   Nature Communications

Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study

(2016) Zheng Wang et al.   Oncotarget

ICOS Co-Stimulation: Friend or Foe?

(2016) Daniel J. Wikenheiser et al.   Frontiers in Immunology

Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer

(2016) Zhenyu Xu et al.   OncoImmunology

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer

(2015) Sima Rahimian et al.   BIOMATERIALS

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential

(2015) Koen van de Ven et al.   Immunotherapy

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus

(2015) Kathy A. Green et al.   JOURNAL OF VIROLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice

(2015) Haniyeh Ghaffari-Nazari et al.   PLoS One

The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma

(2015) Bin Zhang et al.   TUMOR BIOLOGY

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer

(2015) Tao Qin et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Ovarian Cancer Immunotherapy Using PD-L1 siRNA Targeted Delivery from Folic Acid-Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing

(2015) Pei Yun Teo et al.   Advanced Healthcare Materials

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+T cell responses

(2015) Robert J Johnston et al.   OncoImmunology

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients

(2015) David B Page et al.   Journal for ImmunoTherapy of Cancer

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

(2015) Robert D. Leone et al.   Computational and Structural Biotechnology Journal

TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway

(2015) Brian Tomkowicz et al.   PLoS One

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Breast Cancer: Epidemiology and Etiology

(2014) ZiQi Tao et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

(2013) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

(2013) B. Kwong et al.   CANCER RESEARCH

Role of hypoxia-inducible factors in breast cancer metastasis

(2013) Daniele M Gilkes et al.   Future Oncology

Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group

(2013) Maria Regina Jobim et al.   HUMAN IMMUNOLOGY

Anti-CD73 therapy impairs tumor angiogenesis

(2013) Bertrand Allard et al.   INTERNATIONAL JOURNAL OF CANCER

B7-H3-mediated tumor immunology: Friend or foe?

(2013) Ling Wang et al.   INTERNATIONAL JOURNAL OF CANCER

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

(2013) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4+T cells by plasmacytoid dendritic cells

(2013) Julien Faget et al.   OncoImmunology

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

(2012) Jason Park et al.   NATURE MATERIALS

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

(2012) B. Edris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD8+T Cells: GITR Matters

(2012) Simona Ronchetti et al.   TheScientificWorldJOURNAL

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study

(2011) Fengyan Xu et al.   BMC CANCER

TGF-  Signaling Pathway and Breast Cancer Susceptibility

(2011) S. Scollen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

(2011) Kerry S. Campbell et al.   IMMUNOLOGY

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Killer cell immunoglobulin-like receptor genes in patients with breast cancer

(2011) Ozlem Goruroglu Ozturk et al.   MEDICAL ONCOLOGY

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics.

(2011) Z. SLOBODOVA et al.   NEOPLASMA

B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis

(2010) Takaaki Arigami et al.   ANNALS OF SURGERY

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

(2010) M C Ryan et al.   BRITISH JOURNAL OF CANCER

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients

(2010) M. Nagahara et al.   CLINICAL CANCER RESEARCH

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

(2010) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

New Insights of CTLA-4 into Its Biological Function in Breast Cancer

(2010) H. Mao et al.   CURRENT CANCER DRUG TARGETS

B7-H3 Augments the Inflammatory Response and Is Associated with Human Sepsis

(2010) G. Zhang et al.   JOURNAL OF IMMUNOLOGY

Role of CD27/CD70 pathway of activation in immunity and tolerance

(2010) Julie Denoeud et al.   JOURNAL OF LEUKOCYTE BIOLOGY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: An immunohistochemistry-based pilot study

(2010) Fang Xie et al.   PATHOLOGY RESEARCH AND PRACTICE

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province

(2009) Zhenkun Fu et al.   BREAST CANCER RESEARCH AND TREATMENT

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

(2009) Chao Wang et al.   IMMUNOLOGICAL REVIEWS

The significance of OX40 and OX40L to T-cell biology and immune disease

(2009) Michael Croft et al.   IMMUNOLOGICAL REVIEWS

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

Cutting Edge: A Critical Role of B and T Lymphocyte Attenuator in Peripheral T Cell Tolerance Induction

(2009) X. Liu et al.   JOURNAL OF IMMUNOLOGY

The role of CD40 and CD154/CD40L in dendritic cells

(2009) Daphne Y. Ma et al.   SEMINARS IN IMMUNOLOGY

Nanotechnology for breast cancer therapy

(2008) Takemi Tanaka et al.   BIOMEDICAL MICRODEVICES

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY

Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek

(2008) G. J. Freeman   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA